Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
about
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@en
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@nl
type
label
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@en
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@nl
prefLabel
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@en
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@nl
P2093
P2860
P356
P1476
Bioavailability, safety, and p ...... tablets or one 60 mg capsule.
@en
P2093
Maria Claudia Perez
Michael Kukulka
Sai Nudurupati
P2860
P304
P356
10.1177/1756283X16666800
P577
2016-09-25T00:00:00Z